Orexo Ab operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Orexo Ab with three other
pharmaceutical manufacturers in Europe:
sales of 332.44 million Romanian Leu [US$83.63 million]
Solon Eiendom ASA
(691.50 million Norwegian Kroner [US$84.75 million]
of which 114%
was Residential Real Estate), and
Bosnalijek d.d. Sarajevo
based in Bosnia
(135.81 million Bosnian Convertible Marks [US$79.28 million]
During the year ended December of 2016, sales at
Orexo Ab were SEK 705.90 million (US$85.15 million).
increase of 9.7%
versus 2015, when the company's sales were SEK 643.34 million.
This was the fifth consecutive year of sales increases at Orexo Ab
(and since 2011, sales have increased a total of 254%).
Sales of Zubsolv saw an increase
15.6% in 2016, from
SEK 416.70 million to SEK 481.80 million.
Not all segments of Orexo Ab experienced an increase in sales in 2016:
sales of Milestone Payment Abstral fell 96.7% to SEK 2.20 million.
Orexo Ab also experienced decreases in sales in
Royalty - Abstral (down 25.2% to SEK 100.40 million)